22.07.2020 • News

KBR Wins China, India Projects

Engineering and construction group KBR has won contracts on two separate projects in China and India. The first will see it supply its proprietary catalyst for Shenghong Refining Petrochemical’s proposed vinyl acetate monomer (VAM) project in Lianyungang, China. The plant will have a capacity of 300,000 t/y – an on-stream date was not revealed.

KBR said the contract represents the first commercial VAM technology license and engineering contract under an alliance with Japan's Showa Denko. The partners agreed in February 2015 that KBR would exclusively license Showa Denko's acetyls technologies worldwide, which include glacial acetic acid, VAM, ethyl acetate n-propyl acetate and allyl alcohol processes for epichlorohydrin technology. Additionally, KBR will provide engineering support to deliver the license packages to customers.  

Indian chemical producer Kutch Specialities has also contracted KBR to provide its proprietary Plinke adiabatic nitrobenzene process for a new plant in Gujarat. KBR will provide basic and detailed engineering design, equipment and related advisory services. 

No further details on the project were given.

KBR has won two contracts for projects in China and India. The first will see...
KBR has won two contracts for projects in China and India. The first will see KBR supply its proprietary catalyst for Shenghong Refining Petrochemical (Lianyungang) Co's vinyl acetate monomer project in China. The second is for nitrobenzene technology for Kutch Specialities. (c) KBR

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read